AU2017317651B2 - Compounds for treating diseases associated with a mitochondrial dysfonction - Google Patents
Compounds for treating diseases associated with a mitochondrial dysfonction Download PDFInfo
- Publication number
- AU2017317651B2 AU2017317651B2 AU2017317651A AU2017317651A AU2017317651B2 AU 2017317651 B2 AU2017317651 B2 AU 2017317651B2 AU 2017317651 A AU2017317651 A AU 2017317651A AU 2017317651 A AU2017317651 A AU 2017317651A AU 2017317651 B2 AU2017317651 B2 AU 2017317651B2
- Authority
- AU
- Australia
- Prior art keywords
- group
- carbon atoms
- compound
- formula
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306094.0A EP3290039B1 (en) | 2016-08-30 | 2016-08-30 | Compounds for treating diseases associated with a mitochondrial dysfonction |
| EP16306094.0 | 2016-08-30 | ||
| PCT/EP2017/071812 WO2018041919A1 (en) | 2016-08-30 | 2017-08-30 | Compounds for treating diseases associated with a mitochondrial dysfonction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017317651A1 AU2017317651A1 (en) | 2019-03-07 |
| AU2017317651B2 true AU2017317651B2 (en) | 2022-12-15 |
Family
ID=56896495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017317651A Expired - Fee Related AU2017317651B2 (en) | 2016-08-30 | 2017-08-30 | Compounds for treating diseases associated with a mitochondrial dysfonction |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10857135B2 (enExample) |
| EP (2) | EP3290039B1 (enExample) |
| JP (1) | JP7065854B2 (enExample) |
| KR (1) | KR20200011927A (enExample) |
| CN (1) | CN110035758B (enExample) |
| AU (1) | AU2017317651B2 (enExample) |
| BR (1) | BR112019004236A2 (enExample) |
| CA (1) | CA3034694A1 (enExample) |
| ES (1) | ES2800917T3 (enExample) |
| MA (1) | MA46099A (enExample) |
| MX (1) | MX394782B (enExample) |
| RU (1) | RU2019108824A (enExample) |
| SG (1) | SG11201901689YA (enExample) |
| WO (1) | WO2018041919A1 (enExample) |
| ZA (1) | ZA201900997B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2800917T3 (es) * | 2016-08-30 | 2021-01-05 | Amabiotics | Compuestos para tratar enfermedades asociadas con una disfunción mitocondrial |
| KR20210005848A (ko) * | 2018-03-07 | 2021-01-15 | 아마바이오틱스 | 알츠하이머병을 치료하기 위한 화합물 |
| US20220096574A1 (en) * | 2019-01-29 | 2022-03-31 | Holobiome, Inc. | Methods and compositions for treating and preventing central nervous system disorders and other conditions caused by gut microbial dysbiosis |
| EP4028014A1 (en) * | 2019-09-12 | 2022-07-20 | Stellate Therapeutics | Compounds for treating neurodegenerative diseases |
| WO2021048431A1 (en) * | 2019-09-12 | 2021-03-18 | Amabiotics | Compounds for treating ataxia |
| CN116850191A (zh) * | 2023-06-16 | 2023-10-10 | 山东大学齐鲁医院 | 奎因在制备治疗线粒体功能障碍相关疾病药物中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996033703A2 (en) * | 1995-04-25 | 1996-10-31 | Oridigm Corporation | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
| WO2016050804A1 (en) * | 2014-09-29 | 2016-04-07 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5936615A (ja) * | 1982-08-24 | 1984-02-28 | Takeda Chem Ind Ltd | 発がん予防剤 |
| US6020139A (en) * | 1995-04-25 | 2000-02-01 | Oridigm Corporation | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
| FR3002139B1 (fr) * | 2013-02-21 | 2015-06-19 | Amabiotics | Utilisation cosmetique de la queuine |
| GB201417165D0 (en) | 2014-09-29 | 2014-11-12 | Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin | Treatments for Autoimmune Disease |
| ES2800917T3 (es) * | 2016-08-30 | 2021-01-05 | Amabiotics | Compuestos para tratar enfermedades asociadas con una disfunción mitocondrial |
-
2016
- 2016-08-30 ES ES16306094T patent/ES2800917T3/es active Active
- 2016-08-30 EP EP16306094.0A patent/EP3290039B1/en active Active
-
2017
- 2017-08-30 AU AU2017317651A patent/AU2017317651B2/en not_active Expired - Fee Related
- 2017-08-30 RU RU2019108824A patent/RU2019108824A/ru unknown
- 2017-08-30 CN CN201780053445.8A patent/CN110035758B/zh active Active
- 2017-08-30 MA MA046099A patent/MA46099A/fr unknown
- 2017-08-30 EP EP17771680.0A patent/EP3506903A1/en active Pending
- 2017-08-30 SG SG11201901689YA patent/SG11201901689YA/en unknown
- 2017-08-30 US US16/328,784 patent/US10857135B2/en active Active
- 2017-08-30 JP JP2019532202A patent/JP7065854B2/ja active Active
- 2017-08-30 WO PCT/EP2017/071812 patent/WO2018041919A1/en not_active Ceased
- 2017-08-30 BR BR112019004236A patent/BR112019004236A2/pt not_active IP Right Cessation
- 2017-08-30 MX MX2019002369A patent/MX394782B/es unknown
- 2017-08-30 KR KR1020197008753A patent/KR20200011927A/ko not_active Abandoned
- 2017-08-30 CA CA3034694A patent/CA3034694A1/en active Pending
-
2019
- 2019-02-15 ZA ZA2019/00997A patent/ZA201900997B/en unknown
-
2020
- 2020-11-02 US US17/086,583 patent/US11684611B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996033703A2 (en) * | 1995-04-25 | 1996-10-31 | Oridigm Corporation | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
| WO2016050804A1 (en) * | 2014-09-29 | 2016-04-07 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases |
Non-Patent Citations (1)
| Title |
|---|
| Randerath, Cancer Research, vol. 44, 1167-1171, Mar. 1984. (Year: 1984). * |
Also Published As
| Publication number | Publication date |
|---|---|
| US11684611B2 (en) | 2023-06-27 |
| CN110035758B (zh) | 2023-06-16 |
| JP2019526634A (ja) | 2019-09-19 |
| US20210046056A1 (en) | 2021-02-18 |
| EP3290039B1 (en) | 2020-03-25 |
| CN110035758A (zh) | 2019-07-19 |
| MA46099A (fr) | 2019-07-10 |
| BR112019004236A2 (pt) | 2019-05-28 |
| ZA201900997B (en) | 2020-05-27 |
| US10857135B2 (en) | 2020-12-08 |
| MX394782B (es) | 2025-03-24 |
| WO2018041919A1 (en) | 2018-03-08 |
| MX2019002369A (es) | 2019-11-07 |
| RU2019108824A (ru) | 2020-10-01 |
| US20190224174A1 (en) | 2019-07-25 |
| ES2800917T3 (es) | 2021-01-05 |
| KR20200011927A (ko) | 2020-02-04 |
| EP3290039A1 (en) | 2018-03-07 |
| JP7065854B2 (ja) | 2022-05-12 |
| SG11201901689YA (en) | 2019-03-28 |
| AU2017317651A1 (en) | 2019-03-07 |
| CA3034694A1 (en) | 2018-03-08 |
| EP3506903A1 (en) | 2019-07-10 |
| RU2019108824A3 (enExample) | 2020-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017317651B2 (en) | Compounds for treating diseases associated with a mitochondrial dysfonction | |
| Ebrahimi-Fakhari et al. | Protein degradation pathways in Parkinson’s disease: curse or blessing | |
| KR101964954B1 (ko) | 뉴로트로핀 수용체의 효현제 및 약제로서의 이의 용도 | |
| Jain-Vakkalagadda et al. | Identification and functional characterization of a Na+-independent large neutral amino acid transporter, LAT1, in human and rabbit cornea | |
| Passemard et al. | Endoplasmic reticulum and Golgi stress in microcephaly | |
| CN111051316B (zh) | 五环化合物 | |
| Zhang et al. | Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets | |
| Kwon et al. | Korean Red Ginseng and Rb1 facilitate remyelination after cuprizone diet-induced demyelination | |
| JP4169597B2 (ja) | 神経変性疾患の処置のためのトリペプチド及びトリペプチド誘導体 | |
| US20230040247A1 (en) | Compounds for treating neurodegenerative diseases | |
| CA3093212A1 (en) | Compounds for treating alzheimer's disease | |
| WO2021048431A1 (en) | Compounds for treating ataxia | |
| Galione et al. | Stereospecific rapid activation of Transcription Factor EB (TFEB) by Levacetylleucine (NALL) | |
| Chen et al. | 20 (S)-protopanaxadiol targets brain-enriched adenylate kinase 5 to improve cognitive function via regulating hippocampal neural plasticity | |
| Zhao et al. | Extracellular vesicle-based bumetanide delivery alleviates depression-like behaviors of male mice by restoring chloride homeostasis | |
| WO2003045325A2 (en) | Dopaminergic stimulatory factor | |
| CA3239213A1 (en) | Sco-spondin-derived polypeptides for treating biological barriers dysfunction | |
| Balimane | Characterizing the interactions of a non-peptide drug with the intestinal peptide transporter, hPEPT1 | |
| HK40022802A (en) | Pentacyclic compound | |
| HK40022802B (en) | Pentacyclic compound | |
| Shuang et al. | Effect of Low Level of DMSO on Cell Survival Rate and Amino Acid Metabolism in SH-SY5Y Cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK25 | Application lapsed reg. 22.2i(2) - failure to pay acceptance fee |